The impact of over-the-counter availability of nasal sprays on sales, prescribing, and physician visits

Citation
L. Lundberg et D. Isacson, The impact of over-the-counter availability of nasal sprays on sales, prescribing, and physician visits, SC J PRIM H, 17(1), 1999, pp. 41-45
Citations number
23
Categorie Soggetti
Health Care Sciences & Services
Journal title
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE
ISSN journal
02813432 → ACNP
Volume
17
Issue
1
Year of publication
1999
Pages
41 - 45
Database
ISI
SICI code
0281-3432(199903)17:1<41:TIOOAO>2.0.ZU;2-W
Abstract
Objective - The aim was to study changes in sales and prescribing of nasal decongestants containing oxymetazoline or xylometazoline, changes in number of physician visits for rhinitis and sinusitis, and changes in public expe nditures for physician visits due to the switch of these drugs from prescri ption to over-the-counter status in Sweden in 1989. Design - Retrospective registry study using the local sales statistics on medicines in the municip ality of Tierp from The National Corporation of Swedish Pharmacies and the individual-based computerised registry in Tierp based on health care utilis ation and drug use from the Centre for Primary Care. Analyses were carried out during the time period 1988-1995. Setting - The Swedish community of Tierp with about 20 000 inhabitants. Subjects - The population of Tierp. Main outcome measure - Sales of nasal decongestants and dispensed prescript ions of nasal decongestants, physician visits for rhinitis and sinusitis, a nd public expenditures for these. Results - Sales of nasal sprays increased, while sales of nasal drops decre ased, The number of dispensed prescriptions as well as physician visits dec reased. The public expenditures estimated for physician visits decreased as well. Conclusion - This study shows an increase in sales of nasal decongestants a nd a significant decrease in prescribing of nasal decongestants and the num ber of physician visits for rhinitis and sinusitis as well as the public ex penditures estimated for these, after the switch from prescription to over- the counter status of nasal sprays in 1989.